LeadIQ logo
Learn more at LeadIQ.com
✕

Access Insights for Myeloid Therapeutics and Millions of Other Companies

Sign up for full access to Myeloid Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Insights

Expansion into Asia-Pacific Myeloid Therapeutics Inc. recently launched Aurora Biosynthetics to meet the growing RNA therapeutics demand in the Asia-Pacific region. This expansion presents a key sales opportunity for Myeloid to tap into a new market and establish a strong presence in the region.

Key Hires in Leadership Roles Myeloid Therapeutics Inc. has appointed experienced professionals like Robert Hofmeister as Chief Scientific Officer and Matthew Maurer as Chief Medical Officer. Leveraging the expertise of these key leaders can enhance the company's credibility and open doors for potential collaborations and sales opportunities.

Cutting-Edge GMP Manufacturing Facility Myeloid Therapeutics Inc. launched a state-of-the-art GMP manufacturing RNA facility, showcasing their commitment to quality and innovation. This facility can serve as a unique selling point for attracting partners and customers looking for advanced manufacturing capabilities in the biotechnology sector.

Clinical Pipeline Advancements Myeloid Therapeutics Inc. is actively developing MT-101, a promising cell therapy programme in Phase I/II trials for T cell lymphoma. Progress in the clinical pipeline presents a compelling sales narrative, offering potential customers access to cutting-edge therapies and novel treatment options.

Strong Financial Backing With a solid funding of $73 million and a revenue ranging between $0-10 million, Myeloid Therapeutics Inc. demonstrates financial stability and growth potential. This financial robustness not only instills confidence in potential partners and investors but also signifies the company's capacity for future expansion and sales growth.

Similar companies to Myeloid Therapeutics

✕

Access Insights for Myeloid Therapeutics and Millions of Other Companies

Sign up for full access to Myeloid Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Myeloid Therapeutics Tech Stack

Myeloid Therapeutics uses 8 technology products and services including MySQL, Google Cloud, RequireJS, and more. Explore Myeloid Therapeutics's tech stack below.

  • MySQL
    Database
  • Google Cloud
    Infrastructure As A Service
  • RequireJS
    Javascript Frameworks
  • Slick
    Javascript Libraries
  • Open Graph
    Miscellaneous
  • PHP
    Programming Languages
  • Cloudflare Bot Management
    Security
  • Contact Form 7
    Web Platform Extensions

Media & News

Myeloid Therapeutics's Email Address Formats

Myeloid Therapeutics uses at least 1 format(s):
Myeloid Therapeutics Email FormatsExamplePercentage
FLast@myeloidtx.comJDoe@myeloidtx.com
91%
FMiddleLast@myeloidtx.comJMichaelDoe@myeloidtx.com
4%
First@myeloidtx.comJohn@myeloidtx.com
3%
FirstLast@myeloidtx.comJohnDoe@myeloidtx.com
2%

Frequently Asked Questions

Where is Myeloid Therapeutics's headquarters located?

Minus sign iconPlus sign iconMyeloid Therapeutics's main headquarters is located at 300 Technology Sq 2nd Floor Cambridge, Massachusetts 02139 US. The company has employees across 2 continents, including North AmericaEurope.

What is Myeloid Therapeutics's official website and social media links?

Minus sign iconPlus sign iconMyeloid Therapeutics's official website is myeloidtx.com and has social profiles on LinkedIn.

How much revenue does Myeloid Therapeutics generate?

Minus sign iconPlus sign icon As of October 2024, Myeloid Therapeutics's annual revenue reached $3.8M.

What is Myeloid Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign iconMyeloid Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Myeloid Therapeutics have currently?

Minus sign iconPlus sign iconAs of October 2024, Myeloid Therapeutics has approximately 53 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer & Co-Founder: D. G.Chief People Officer: C. D.Chief Business Officer: D. B.. Explore Myeloid Therapeutics's employee directory with LeadIQ.

What industry does Myeloid Therapeutics belong to?

Minus sign iconPlus sign iconMyeloid Therapeutics operates in the Biotechnology Research industry.

What technology does Myeloid Therapeutics use?

Minus sign iconPlus sign iconMyeloid Therapeutics's tech stack includes MySQLGoogle CloudRequireJSSlickOpen GraphPHPCloudflare Bot ManagementContact Form 7.

What is Myeloid Therapeutics's email format?

Minus sign iconPlus sign iconMyeloid Therapeutics's email format typically follows the pattern of . Find more Myeloid Therapeutics email formats with LeadIQ.

How much funding has Myeloid Therapeutics raised to date?

Minus sign iconPlus sign icon As of October 2024, Myeloid Therapeutics has raised $73M in funding. The last funding round occurred on May 18, 2023 for $73M.
Myeloid Therapeutics

Myeloid Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells. We have translated the learnings from our backgrounds and novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer.

We invite you to join us on this journey – patients are waiting.

✕

Access Insights for Myeloid Therapeutics and Millions of Other Companies

Sign up for full access to Myeloid Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Section iconCompany Overview

Headquarters
300 Technology Sq 2nd Floor Cambridge, Massachusetts 02139 US
Website
myeloidtx.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $73M

    Myeloid Therapeutics has raised a total of $73M of funding over 3 rounds. Their latest funding round was raised on May 18, 2023 in the amount of $73M.

  • $10M

    Myeloid Therapeutics's revenue is in the range of $10M

Section iconFunding & Financials

  • $73M

    Myeloid Therapeutics has raised a total of $73M of funding over 3 rounds. Their latest funding round was raised on May 18, 2023 in the amount of $73M.

  • $10M

    Myeloid Therapeutics's revenue is in the range of $10M

Company Leadership

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

✕

Access Insights for Myeloid Therapeutics and Millions of Other Companies

Sign up for full access to Myeloid Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.